The passion, determination and expertise of Olgram’s management and founders have led to many important developments in the field of medicine, they are driven by innovation and the improvement of the quality of life of patients around the world.
Maryvonne created Olgram in 2019. She has built the company strategy, management team and executed the development plan since then. Before that Maryvonne led during 14 years a nuclear program at FRAMATOME (Areva). She also led during 20 years different innovative society in the biotechnology sector including SangStat Atlantic (acquired by Genzyme in 2003 to increase its portfolio on immunosuppression and transplantation products), DrugAbuse Sciences and TcLand.
After a PhD in biology at the Pasteur institute, an MBA at ESCP-Europe, 4 years as a consultant in business strategy and 4 years as director in charge of the human care department at the Olmix group, Pierre founded Olgram in 2019, a biopharmaceutical company working on eliminating the root of the chronic infectious diseases by eliminating the pathogens responsible for the recalcitrance of the diseases.
Olgram’s teams are made up of dedicated and passionate professionals, working together to improve the lives of people around the world using the latest advances in biotechnology.